Arca
Skip to content

Rosuvastatin Calcium

ANDA 79172, held by Glenmark Speclt. Rosuvastatin Calcium.

  • First approved: Jul 19, 2016
  • Supplements approved: 9
  • Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 10 submissions below
DateSubmissionStatusDocuments
Jul 19, 2016Original applicationApprovedLetter

Products

4 strengths and forms
ProductActive ingredientMarketing
Rosuvastatin CalciumEQ 5MG BASE · tablet;oralRosuvastatin CalciumRx
Rosuvastatin CalciumEQ 10MG BASE · tablet;oralRosuvastatin CalciumRx
Rosuvastatin CalciumEQ 20MG BASE · tablet;oralRosuvastatin CalciumRx
Rosuvastatin CalciumEQ 40MG BASE · tablet;oralRosuvastatin CalciumRx
All 10 submissions, including labeling and manufacturing supplements
DateSubmissionStatusDocuments
Aug 17, 2026Supplement 31Labeling · Standard reviewApprovedNone posted
Oct 15, 2024Supplement 24Labeling · Standard reviewApprovedNone posted
Feb 2, 2024Supplement 18Labeling · Standard reviewApprovedNone posted
Jul 13, 2023Supplement 7Labeling · Standard reviewApprovedNone posted
Jul 13, 2023Supplement 10Labeling · Standard reviewApprovedNone posted
Jul 13, 2023Supplement 14Labeling · Standard reviewApprovedNone posted
Jul 13, 2023Supplement 15Labeling · Standard reviewApprovedNone posted
Mar 9, 2020Supplement 1Labeling · Standard reviewApprovedNone posted
Mar 9, 2020Supplement 2Labeling · Standard reviewApprovedNone posted
Jul 19, 2016Original applicationApprovedLetter

Identifiers

Application
ANDA 79172

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.